Home › NDC Lookup › RxCUI directory › RxCUI 1368012

Alogliptin 25 MG Oral Tablet [Nesina] — RxCUI 1368012

Name: Alogliptin 25 MG Oral Tablet [Nesina] (RxCUI 1368012)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1368012 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 10 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1368012

Official nameAlogliptin 25 MG Oral Tablet [Nesina]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asNesina 25 MG Oral Tablet; Nesina 25 MG (as alogliptin benzoate 34 MG) Oral Tablet

FDA products mapped3

Package NDCs mapped10

Reported Medicaid activity (SDUD)205 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Alogliptin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

After you eat, your gut releases natural hormones that signal your pancreas to release insulin. An enzyme in your body called DPP-4 normally destroys those hormones within minutes....
What exactly does alogliptin do — how does it lower my blood sugar?
It depends on how well your kidneys are working. Since alogliptin is mostly cleared through the kidneys, your prescriber will likely lower your dose if your kidney function is redu...
Can I take alogliptin if I have kidney problems?

📖 Read our full Alogliptin guide →

🕸️ Concept Web — How Alogliptin 25 MG Oral Tablet [Nesina] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Alogliptin 25 MG Oral Tablet [Nesina] RxCUI 1368012 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Alogliptin 1368001 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Nesina 1368007 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Alogliptin Oral Tablet 1368005 SCDF
- Alogliptin Oral Product 1368003 SCDG
- Alogliptin Pill 1368004 SCDG
- Alogliptin Oral Tablet [Nesina] 1368009 SBDF
- Nesina Oral Product 1368010 SBDG
- Nesina Pill 1368011 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Alogliptin 25 MG Oral Tablet 1368006 SCD
- Alogliptin 25 MG 1368002 SCDC
- Alogliptin 25 MG [Nesina] 1368008 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Alogliptin 25 MG Oral Tablet SCD · 1368006
Alogliptin 25 MG SCDC · 1368002
Alogliptin Oral Tablet SCDF · 1368005
Alogliptin Oral Product SCDG · 1368003
Alogliptin Pill SCDG · 1368004

Brand-Name Concepts

Alogliptin 25 MG [Nesina] SBDC · 1368008
Alogliptin Oral Tablet [Nesina] SBDF · 1368009
Nesina Oral Product SBDG · 1368010
Nesina Pill SBDG · 1368011
Nesina BN · 1368007

📦 FDA Products & Package NDCs

3 products · 10 package NDCs

10 package NDCs map to RxCUI 1368012 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
64764-0125-02	4 CARTON in 1 TRAY (64764-125-02) / 1 BLISTER PACK in 1 CAR...	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0125-30	30 TABLET, FILM COATED in 1 BOTTLE (64764-125-30)	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0125-50	500 TABLET, FILM COATED in 1 BOTTLE (64764-125-50)	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0125-90	90 TABLET, FILM COATED in 1 BOTTLE (64764-125-90)	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0250-02	4 CARTON in 1 TRAY (64764-250-02) / 1 BLISTER PACK in 1 CAR...	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0250-30	30 TABLET, FILM COATED in 1 BOTTLE (64764-250-30)	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0250-50	500 TABLET, FILM COATED in 1 BOTTLE (64764-250-50)	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0250-90	90 TABLET, FILM COATED in 1 BOTTLE (64764-250-90)	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0625-30	30 TABLET, FILM COATED in 1 BOTTLE (64764-625-30)	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25
64764-0625-90	90 TABLET, FILM COATED in 1 BOTTLE (64764-625-90)	Nesina	Takeda Pharmaceuticals America, Inc.	2013-01-25

Observed labelers: Takeda Pharmaceuticals America, Inc. (10) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.